Europe Stem Cell Therapy Market - Industry Trends and Forecast to 2029

Description

List of Tables

The Europe stem cell therapy market is projected to register a substantial CAGR of 10.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2020, and the forecast period is 2022 to 2029

Market Segmentation:

Europe Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (Italy, Belgium, Czech Republic, Germany, U.K., Spain, Hungary, and Poland) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Europe stem cell therapy market are:

The rise in good manufacturing practice certifications for the setup of stem cell manufacturing facilities in Europe

Rise in healthcare infrastructure in Europe

Market Players:

Some of the major players operating in the Europe stem cell therapy market are:

Takeda Pharmaceutical Company Limited

Holostem Terapie Avanzate S.r.l.

JCR Pharmaceuticals Co., Ltd

ANTEROGEN.CO., LTD

MEDIPOST

Orthofix Medical Inc.

BioRestorative Therapies, Inc.

STEMPEUTICS RESEARCH PVT LTD

Pluristem Inc.

1 INTRODUCTION 15

1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 OVERVIEW OF THE EUROPE STEM CELL THERAPY MARKET 16
1.4 CURRENCY AND PRICING 18
1.5 LIMITATIONS 18
1.6 MARKETS COVERED 18

2 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION 20

2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 DBMR TRIPOD DATA VALIDATION MODEL 23
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT SEGMENT LIFELINE CURVE 27
2.8 DBMR MARKET POSITION GRID 28
2.9 VENDOR SHARE ANALYSIS 30
2.10 MARKET END USER COVERAGE GRID 31
2.11 SECONDARY SOURCES 32

3 EXECUTIVE SUMMARY 33

4 PREMIUM INSIGHTS 37

4.1 PESTEL 38
4.2 PORTER'S FIVE FORCES MODEL 39

5 EPIDEMIOLOGY 40

6 PIPELINE ANALYSIS FOR THE EUROPE STEM CELL THERAPY MARKET 41

7 EUROPE STEM CELL THERAPY MARKET: REGULATIONS 42

8 MARKET OVERVIEW 45

8.1 DRIVERS 47
- 8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 47
- 8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 48
- 8.1.3 GROWING BIOTECHNOLOGY SECTOR 49
- 8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 50
- 8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 50
8.2 RESTRAINTS 51
- 8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 51
- 8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 51
- 8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 52
- 8.2.4 AVAILABILITY OF ALTERNATIVES 52
8.3 OPPORTUNITIES 53
- 8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 53
- 8.3.2 RISE IN HEALTHCARE EXPENDITURE 53
- 8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 54
8.4 CHALLENGES 54
- 8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 54
- 8.4.2 STRINGENT REGULATIONS 55

9 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE 57

9.1 OVERVIEW 58
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 61
9.3 PLACENTAL/UMBILICAL STEM CELL 61
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 62
9.5 OTHERS 63

10 EUROPE STEM CELL THERAPY MARKET, BY TYPE 65

10.1 OVERVIEW 66
10.2 ALLOGENEIC STEM CELL THERAPY 69
- 10.2.1 MUSCULOSKELETAL DISORDERS 70
- 10.2.2 WOUNDS AND INJURIES 70
- 10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 70
- 10.2.4 SURGERIES 70
- 10.2.5 GASTROINTESTINAL DISEASES 70
- 10.2.6 OTHER APPLICATION 70

10.3 AUTOLOGOUS STEM CELL THERAPY 70
- 10.3.1 CARDIOVASCULAR DISEASES 72
- 10.3.2 GASTROINTESTINAL DISEASES 72
- 10.3.3 OTHER APPLICATION 72

11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION 73

11.1 OVERVIEW 74
11.2 MUSCULOSKELETAL DISORDERS 76
11.3 WOUNDS AND INJURIES 77
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 78
11.5 SURGERIES 79
11.6 GASTROINTESTINAL DISEASES 80
11.7 CARDIOVASCULAR DISEASES 80
11.8 OTHER APPLICATION 81

12 EUROPE STEM CELL THERAPY MARKET, BY END USER 83

12.1 OVERVIEW 84
12.2 HOSPITAL AND SURGICAL CENTERS 87
12.3 THERAPEUTIC COMPANIES 87
12.4 SERVICES COMPANIES 88
12.5 OTHERS 89

13 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 90

13.1 OVERVIEW 91
13.2 DIRECT TENDER 95
13.3 THIRD PARTY DISTRIBUTORS 95

14 EUROPE STEM CELL THERAPY MARKET, BY REGION 97

14.1 EUROPE 98
- 14.1.1 ITALY 104
- 14.1.2 BELGIUM 106
- 14.1.3 CZECH REPUBLIC 108
- 14.1.4 GERMANY 110
- 14.1.5 U.K. 112
- 14.1.6 SPAIN 114
- 14.1.7 HUNGARY 116
- 14.1.8 POLAND 118

15 EUROPE STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 120

15.1 COMPANY SHARE ANALYSIS: EUROPE 120

16 SWOT ANALYSIS 121

17 COMPANY PROFILE 122

17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 122
- 17.1.1 COMPANY SNAPSHOT 122
- 17.1.2 REVENUE ANALYSIS 122
- 17.1.3 COMPANY SHARE ANALYSIS 123
- 17.1.4 PRODUCT PORTFOLIO 123
- 17.1.5 RECENT DEVELOPMENT 123
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 124
- 17.2.1 COMPANY SNAPSHOT 124
- 17.2.2 REVENUE ANALYSIS 124
- 17.2.3 COMPANY SHARE ANALYSIS 125
- 17.2.4 PRODUCT PORTFOLIO 125
- 17.2.5 RECENT DEVELOPMENTS 125
17.3 ORTHOFIX MEDICAL INC. (2021) 126
- 17.3.1 COMPANY SNAPSHOT 126
- 17.3.2 REVENUE ANALYSIS 126
- 17.3.3 COMPANY SHARE ANALYSIS 127
- 17.3.4 PRODUCT PORTFOLIO 127
- 17.3.5 RECENT DEVELOPMENTS 127
17.4 MEDIPOST (2021) 129
- 17.4.1 COMPANY SNAPSHOT 129
- 17.4.2 REVENUE ANALYSIS 129
- 17.4.3 COMPANY SHARE ANALYSIS 130
- 17.4.4 PRODUCT PORTFOLIO 130
- 17.4.5 RECENT DEVELOPMENTS 130
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 132
- 17.5.1 COMPANY SNAPSHOT 132
- 17.5.2 REVENUE ANALYSIS 132
- 17.5.3 COMPANY SHARE ANALYSIS 133
- 17.5.4 PRODUCT PORTFOLIO 133
- 17.5.5 RECENT DEVELOPMENT 133
17.6 CORESTEM, INC. (2021) 134
- 17.6.1 COMPANY SNAPSHOT 134
- 17.6.2 REVENUE ANALYSIS 134
- 17.6.3 PRODUCT PORTFOLIO 135
- 17.6.4 RECENT DEVELOPMENT 135

17.7 PHARMICELL CO., LTD. (2021) 136
- 17.7.1 COMPANY SNAPSHOT 136
- 17.7.2 PRODUCT PORTFOLIO 136
- 17.7.3 RECENT DEVELOPMENTS 136
17.8 ANTEROGEN.CO., LTD (2021) 137
- 17.8.1 COMPANY SNAPSHOT 137
- 17.8.2 PRODUCT PORTFOLIO 137
- 17.8.3 RECENT DEVELOPMENTS 137
17.9 ATHERSYS, INC.(2021) 138
- 17.9.1 COMPANY SNAPSHOT 138
- 17.9.2 REVENUE ANALYSIS 138
- 17.9.3 PRODUCT PORTFOLIO 139
- 17.9.4 RECENT DEVELOPMENTS 139
17.10 BRAINSTORM CELL LIMITED (2021) 140
- 17.10.1 COMPANY SNAPSHOT 140
- 17.10.2 PRODUCT PORTFOLIO 140
- 17.10.3 RECENT DEVELOPMENTS 140
17.11 BIORESTORATIVE THERAPIES, INC. (2021) 142
- 17.11.1 COMPANY SNAPSHOT 142
- 17.11.2 REVENUE ANALYSIS 142
- 17.11.3 PRODUCT PORTFOLIO 143
- 17.11.4 RECENT DEVELOPMENTS 143
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 144
- 17.12.1 COMPANY SNAPSHOT 144
- 17.12.2 PRODUCT PORTFOLIO 144
- 17.12.3 RECENT DEVELOPMENTS 144
17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 146
- 17.13.1 COMPANY SNAPSHOT 146
- 17.13.2 REVENUE ANALYSIS 146
- 17.13.3 PRODUCT PORTFOLIO 147
- 17.13.4 RECENT DEVELOPMENT 147
17.14 MESOBLAST LTD (2021) 148
- 17.14.1 COMPANY SNAPSHOT 148
- 17.14.2 REVENUE ANALYSIS 148
- 17.14.3 PRODUCT PORTFOLIO 149
- 17.14.4 RECENT DEVELOPMENTS 149

17.15 PLURISTEM INC.(2021) 150
- 17.15.1 COMPANY SNAPSHOT 150
- 17.15.2 REVENUE ANALYSIS 150
- 17.15.3 PRODUCT PORTFOLIO 151
- 17.15.4 RECENT DEVELOPMENT 151
17.16 STEMPEUTICS RESEARCH PVT LTD 152
- 17.16.1 COMPANY SNAPSHOT 152
- 17.16.2 PRODUCT PORTFOLIO 152
- 17.16.3 RECENT DEVELOPMENTS 152
17.17 U.S. STEM CELL, INC. (2021) 154
- 17.17.1 COMPANY SNAPSHOT 154
- 17.17.2 REVENUE ANALYSIS 154
- 17.17.3 PRODUCT PORTFOLIO 155
- 17.17.4 RECENT DEVELOPMENT 155

18 QUESTIONNAIRE 156

19 RELATED REPORTS 159

LIST OF TABLES

TABLE 1 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 60
TABLE 2 EUROPE BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 61
TABLE 3 EUROPE PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 62
TABLE 4 EUROPE ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 63
TABLE 5 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 64
TABLE 6 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 68
TABLE 7 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 69
TABLE 8 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 70
TABLE 9 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 71
TABLE 10 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 71
TABLE 11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 76
TABLE 12 EUROPE MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 13 EUROPE WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 78
TABLE 14 EUROPE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 15 EUROPE SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 16 EUROPE GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 17 EUROPE CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 18 EUROPE OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 82
TABLE 19 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 86
TABLE 20 EUROPE HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 21 EUROPE THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 22 EUROPE SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 23 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 89
TABLE 24 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 94
TABLE 25 EUROPE DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 95
TABLE 26 EUROPE THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION) 96
TABLE 27 EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 102
TABLE 28 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 102
TABLE 29 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 102
TABLE 30 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 102
TABLE 31 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 103
TABLE 32 EUROPE STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 103
TABLE 33 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 103
TABLE 34 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 103
TABLE 35 ITALY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 104
TABLE 36 ITALY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
TABLE 37 ITALY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 104
TABLE 38 ITALY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 104
TABLE 39 ITALY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 105
TABLE 40 ITALY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 41 ITALY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 105
TABLE 42 BELGIUM STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 106
TABLE 43 BELGIUM STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 106
TABLE 44 BELGIUM ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 106
TABLE 45 BELGIUM AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 106
TABLE 46 BELGIUM STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 107
TABLE 47 BELGIUM STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 107
TABLE 48 BELGIUM STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 107
TABLE 49 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 108
TABLE 50 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 108
TABLE 51 CZECH REPUBLIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 108
TABLE 52 CZECH REPUBLIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 108
TABLE 53 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 109
TABLE 54 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 109
TABLE 55 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 109
TABLE 56 GERMANY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 110
TABLE 57 GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
TABLE 58 GERMANY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 110
TABLE 59 GERMANY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 110
TABLE 60 GERMANY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 111
TABLE 61 GERMANY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 111
TABLE 62 GERMANY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 111
TABLE 63 U.K. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 112
TABLE 64 U.K. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 112
TABLE 65 U.K. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 112
TABLE 66 U.K. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 112
TABLE 67 U.K. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 113
TABLE 68 U.K. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 113
TABLE 69 U.K. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 113
TABLE 70 SPAIN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 114
TABLE 71 SPAIN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
TABLE 72 SPAIN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 114
TABLE 73 SPAIN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 114
TABLE 74 SPAIN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 115
TABLE 75 SPAIN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 115
TABLE 76 SPAIN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 115
TABLE 77 HUNGARY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 116
TABLE 78 HUNGARY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
TABLE 79 HUNGARY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 116
TABLE 80 HUNGARY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 116
TABLE 81 HUNGARY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 117
TABLE 82 HUNGARY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 117
TABLE 83 HUNGARY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 117
TABLE 84 POLAND STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION) 118
TABLE 85 POLAND STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION) 118
TABLE 86 POLAND ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 118
TABLE 87 POLAND AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 118
TABLE 88 POLAND STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION) 119
TABLE 89 POLAND STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION) 119
TABLE 90 POLAND STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 119

LIST OF FIGURES

FIGURE 1 EUROPE STEM CELL THERAPY MARKET : SEGMENTATION 20
FIGURE 2 EUROPE STEM CELL THERAPY MARKET: DATA TRIANGULATION 23
FIGURE 3 EUROPE STEM CELL THERAPY MARKET: DROC ANALYSIS 24
FIGURE 4 EUROPE STEM CELL THERAPY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 25
FIGURE 5 EUROPE STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS 25
FIGURE 6 EUROPE STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS 26
FIGURE 7 EUROPE STEM CELL THERAPY MARKET: DBMR POSITION GRID 28
FIGURE 8 EUROPE STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS 30
FIGURE 9 EUROPE STEM CELL THERAPY MARKET: END USER COVERAGE GRID 31
FIGURE 10 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION 35
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 36
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE EUROPE STEM CELL THERAPY MARKET FROM 2022 TO 2029 37
FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE STEM CELL THERAPY MARKET FROM 2022 & 2029 37
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE STEM CELL THERAPY MARKET 46
FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022 47
FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020 48
FIGURE 17 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021 58
FIGURE 18 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 59
FIGURE 19 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 59
FIGURE 20 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE 60
FIGURE 21 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2021 66
FIGURE 22 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION) 67
FIGURE 23 EUROPE STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029) 67
FIGURE 24 EUROPE STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE 68
FIGURE 25 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2021 74
FIGURE 26 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 75
FIGURE 27 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029) 75
FIGURE 28 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE 76
FIGURE 29 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2021 84
FIGURE 30 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION) 85
FIGURE 31 EUROPE STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029) 85
FIGURE 32 EUROPE STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE 86
FIGURE 33 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021 92
FIGURE 34 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 93
FIGURE 35 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 93
FIGURE 36 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 94
FIGURE 37 EUROPE STEM CELL THERAPY MARKET: SNAPSHOT (2021) 99
FIGURE 38 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021) 100
FIGURE 39 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029) 100
FIGURE 40 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029) 101
FIGURE 41 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022 & 2029) 101
FIGURE 42 EUROPE STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%) 120